Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck KGaA
Woman and Man Max 99 years
Merck KGaA (Germany)
Update Il y a 4 ans
Radiotherapy (intensity-modulated radiation therapy [IMRT]), Erbitux® And CHemotherapy for unresectable carcinomas of head and neck
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
A clinical trial to evaluate the mechanism of action and the safety of the cancer vaccine L-BLP25 in rectal cancer subjects undergoing treatment with chemotherapy and radiotherapy
The objective of this mechanistic study is to determine the impact of L-BLP25 vaccine on the mucinous glycoprotein 1 - (MUC1) specific immune response in patients with newly diagnosed rectal cancer wh...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
A Phase I/II, Open Label, Dose-Escalating Study Evaluating the Safety and Efficacy of the Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody EMD 72000 (Matuzumab) in Combination with the EGFR Tyrosine Kinase Inhibitor Tarceva (Erlotinib) in Subjects with Recurrent Advanced Non-Small-Cell Lung Cancer
Primary Objective Phase I: •To determine the safety of matuzumab in combination with erlotinib in up to 5 different dose cohorts. Primary Objective Phase II: •To determine the tumor response rate (R...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
MSB11022 in moderate to severe plaque psoriasis
The primary objective of the trial is to demonstrate equivalence in efficacy of MSB11022 in subjects with moderate to severe chronic plaque psoriasis.
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Merck KGaA
Update Il y a 4 ans
A study to compare Pergoveris and GONAL-f in women who have responded poorly to previous infertiliy treatment cycles
The primary objective of the trial is to demonstrate superiority of Pergoveris® versus GONAL-f® in poor ovarian response (POR) patients.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
An open-label, randomized, controlled, multi-center, Phase I/II trial investigating 2 EMD 525797 doses in combination with cetuximab + irinotecan versus cetuximab + irinotecan alone, as second-line treatment for subjects with k-ras wild type (WT) metastatic colorectal cancer (mCRC). Subjects with k-ras WT mCRC will be eligible for enrollment if they are refractory to or progressive after first-line chemotherapy with an oxaliplatin-containing therapeutic regimen
The primary objectives are: • To characterize the safety and tolerability profile of repeated administration of different EMD 525797 dose levels in combination with cetuximab and irinotecan in subject...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Merck KGaA
Update Il y a 6 ans
Étude EMR 100070-005 : étude de phase 3 comparant l’avélumab avec un doublet à base de platine comme traitement de première ligne chez des patients ayant un cancer de poumon non à petites cellules récurrent ou de stade IV et positif pour PD-L1.
Le cancer de poumon non à petites cellules est le type de cancer de poumon le plus fréquent, qui représente 85-90% de l’ensemble des cancers de poumon. Les traitements principaux du cancer du poumon n...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Immunothérapie - Vaccinothérapie
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Cilengitide in subjects with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter - a multicenter, open-label Phase II study, investigating two cilengitide regimens in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) - CORE
Overall survival time
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Open, randomized, multinational phase IIIb trial evaluating the activity and safety of cetuximab as 250 mg/m² weekly and 500 mg/m² every two weeks maintenance therapy after platinum-based chemotherapy in combination with cetuximab as first-line treatment for subjects with advanced non-small cell lung cancer (NSCLC)
Separate assessment of the activity of each cetuximab maintenance therapy (500 mg/m² every 2 weeks and 250 mg/m² every week) in terms of overall survival time from inclusion in the trial to death in s...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Avelumab in First-Line Gastric Cancer
The primary objectives of this trial are to demonstrate superiority of maintenance therapy with avelumab versus continuation of first-line chemotherapy with regard to Overall Survival (OS) or Progress...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
Next